Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438575 | 0.89 | DPP8 (0.49) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9304084 | 0.87 | DPP7 (0.50) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9304078 | 0.87 | DPP7 (0.50) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL11482808 | 0.86 | SLC15A1 (0.54) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL5671395 | 0.84 | DPP8 (0.52) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9117592 | 0.84 | DPP8 (0.52) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9117596 | 0.84 | DPP8 (0.52) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9637291 | 0.82 | DPP8 (0.46) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL9637284 | 0.82 | DPP8 (0.46) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14065666 | 0.80 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107028792-A | Oligomeric biosurfactants in skin cosmetic compositions | 唐纳德·欧文 | 2017-08-11 | — | — | CN | disclosed |
| US-6916800-B2 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | PFIZER INC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6858598-B1 | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | G. D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-02-17 | — | — | US | disclosed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | PTGS2, PTGES2, PTGS1 | DPP8 2832/4885DPP9 2316/4885DPP7 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.